Schering announces start of three Phase II clinical trials with anti-cancer compound ZK-EPO

European trials will assess ZK-EPO in non-small cell lung, ovarian and breast cancers

02-Dec-2005

Schering AG announced the start of three phase II studies in Europe evaluating its fully synthetic epothilone, ZK-EPO, for the treatment of several types of cancers such as non-small cell lung cancer, ovarian cancer and breast cancer. The clinical trials will assess ZK-EPO's safety and efficacy in each of these cancer types. ZK-EPO is the only fully synthetic epothilone in clinical development. It is designed to improve efficacy and safety compared to the chemotherapies currently available.

In non-small cell lung cancer, a multi-center study is currently enrolling patients in Germany. The trial is designed to examine the efficacy and safety of ZK-EPO as second-line therapy in patients with advanced disease.

The ovarian cancer trial is a multi-center Phase II study that is being conducted in the United Kingdom. The study is currently enrolling patients with recurrent ovarian cancer.

The breast cancer trial will enroll patients in 24 medical centers in a number of European countries. The first study centers have been initiated in France and Austria. The trial will investigate the efficacy of ZK-EPO in patients with metastatic breast cancer.

Additional studies with ZK-EPO are being planned in the United States and the EU.

Other news from the department research and development

More news from our other portals

All FT-IR spectrometer manufacturers at a glance